MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
56.34
+0.77 (+1.39%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close55.57
Open55.57
Bid0.00 x 0
Ask0.00 x 0
Day's Range55.56 - 56.63
52 Week Range53.63 - 66.80
Volume9,770,244
Avg. Volume11,130,498
Market Cap153.495B
Beta0.85
PE Ratio (TTM)54.54
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.92 (3.46%)
Ex-Dividend Date2017-12-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters20 hours ago

    Merck raises stakes in lung cancer as rivals close in

    Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year. In the meantime, Roche Holding AG has shaken up Wall Street expectations for the $15-billion (£11.3 billion) lung cancer market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments.

  • Reuters21 hours ago

    Roche: Tecentriq cocktail slows kidney cancer progression

    Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday. The trial tested the combination against the current standard of care, Pfizer's Sutent, in patients with inoperable, locally advanced or metastatic renal cell carcinoma.

  • Reutersyesterday

    Roche: Tecentriq cocktail slows kidney cancer progression

    Tecentriq, whose sales pale compared to established immunotherapies from Bristol-Myers Squibb and Merck & Co Inc, is a pillar of Roche's plan to replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose expiring patents have exposed them to cheaper competition. As a consequence, Roche is seeking to expand indications and patients eligible for treatment with its drug, which analysts see topping $4.6 billion in annual sales by 2023.

  • Merck & Co Inc (MRK): What You Have To Know Before Buying For The Upcoming Dividend
    Simply Wall St.3 days ago

    Merck & Co Inc (MRK): What You Have To Know Before Buying For The Upcoming Dividend

    Important news for shareholders and potential investors in Merck & Co Inc (NYSE:MRK): The dividend payment of $0.48 per share will be distributed into shareholder on 08 January 2018, andRead More...

  • GuruFocus.com5 days ago

    52-Week Company Lows

    Details the 52-week lows of the following companies: General Electric, Merck & Co, Schlumberger, Enterprise Products Partners, Kinder Morgan and Edison International

  • Why 2017 Was a Year to Forget for Merck & Co. Inc.
    Motley Fool5 days ago

    Why 2017 Was a Year to Forget for Merck & Co. Inc.

    Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.

  • Reuters6 days ago

    Roche to seize leap-frog opportunity in lung cancer

    After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer. "We have a real chance to be at the forefront here," Chief Executive Severin Schwan said on Wednesday.

  • These 3 Stocks Just Raised Their Dividends
    Motley Fool6 days ago

    These 3 Stocks Just Raised Their Dividends

    Shareholders of Walt Disney, Merck, and McCormick are getting some gifts in advance of the holiday season.

  • Top Analyst Reports for Home Depot, Boeing & Merck
    Zacks6 days ago

    Top Analyst Reports for Home Depot, Boeing & Merck

    Top Analyst Reports for Home Depot, Boeing & Merck

  • Biopharma wins in Trump tax bill
    Yahoo Finance Video14 hours ago

    Biopharma wins in Trump tax bill

    One sector that's poised to win big in the Trump tax bill, biopharma. Yahoo Finance's Seana Smith, Andy Serwer and Melody Hahm discuss.

  • Merck lagging this year, but charts show it's poised for ...
    CNBC Videos10 hours ago

    Merck lagging this year, but charts show it's poised for ...

    Carter Worth, Cornerstone Macro, discusses one lagging stock that could make a comeback.

  • Merck CEO on business conditions in China
    CNBC Videos5 days ago

    Merck CEO on business conditions in China

    Merck Chairman and CEO Stefan Oschmann weighs in on the business environment in China and how that has affected the pharmaceutical industry.